Baseline patient characteristics for responders and nonresponders to rituximab, N = 24
. | Responders (range) . | Nonresponders (range) . |
|---|---|---|
| Median age, y | 47 (38-68) | 54.5 (42-81) |
| Male, % | 83 | 87 |
| Median time from HCL diagnosis, mo | 87.5 (30-157) | 98 (24-154) |
| Average number of prior courses of cladribine | 1.4 (1-2) | 1.5 (1-3) |
| Time from last cladribine, mo | 35.9 (22-121) | 72.8 (20-140) |
| Complete remission after last cladribine, % | 66 | 75 |
| Previous splenectomy, % | 0 | 17 |
| Previous interferon, % | 33 | 27 |
| Median bone marrow cellularity consisting of hematopoesis, % | 40 (10-75) | 50 (20-75) |
| Median bone marrow medullary space involved with HCL, % | 17.5 (5-50) | 39 (5-70) |
| Median absolute neutrophil count, × 109/L | 0.9 (0.6-1.4) | 0.8 (0.2-3.3) |
| Median absolute lymphocyte count, × 109/L | 0.6 (0.4-1.0) | 0.8 (0.3-2.4) |
| Median hemoglobin level, g/L | 139 (123-148) | 130 (81-155) |
| Median platelet count, × 109/L | 115 (86-153) | 100 (27-238) |
. | Responders (range) . | Nonresponders (range) . |
|---|---|---|
| Median age, y | 47 (38-68) | 54.5 (42-81) |
| Male, % | 83 | 87 |
| Median time from HCL diagnosis, mo | 87.5 (30-157) | 98 (24-154) |
| Average number of prior courses of cladribine | 1.4 (1-2) | 1.5 (1-3) |
| Time from last cladribine, mo | 35.9 (22-121) | 72.8 (20-140) |
| Complete remission after last cladribine, % | 66 | 75 |
| Previous splenectomy, % | 0 | 17 |
| Previous interferon, % | 33 | 27 |
| Median bone marrow cellularity consisting of hematopoesis, % | 40 (10-75) | 50 (20-75) |
| Median bone marrow medullary space involved with HCL, % | 17.5 (5-50) | 39 (5-70) |
| Median absolute neutrophil count, × 109/L | 0.9 (0.6-1.4) | 0.8 (0.2-3.3) |
| Median absolute lymphocyte count, × 109/L | 0.6 (0.4-1.0) | 0.8 (0.3-2.4) |
| Median hemoglobin level, g/L | 139 (123-148) | 130 (81-155) |
| Median platelet count, × 109/L | 115 (86-153) | 100 (27-238) |